CTLA-2 Alpha Is a Potent Inhibitor of Angiogenesis in Murine Ocular Tissue
Cytotoxic T lymphocyte antigen-2 (CTLA-2) alpha has been reported to suppress the activities of cathepsin L (Cath L), which is deeply involved in angiogenesis. Therefore, we assessed whether CTLA-2 alpha plays a role in angiogenesis in ocular tissue. To establish models of corneal inflammation and e...
Main Authors: | Kazuichi Maruyama, Kazuhito Yoneda, Sunao Sugita, Yoshimi Yamamoto, Masato Koike, Christoph Peters, Yasuo Uchiyama, Kohji Nishida |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/10/3/456 |
Similar Items
-
CRISPR Technology for Ocular Angiogenesis
by: Sook Hyun Chung, et al.
Published: (2020-12-01) -
Topical Nanoemulsion of a Runt-related Transcription Factor 1 Inhibitor for the Treatment of Pathologic Ocular Angiogenesis
by: Santiago Delgado-Tirado, MD, et al.
Published: (2022-09-01) -
Progress of the application of Conbercept in ocular neovascular diseases
by: Xiao-Dong Chen, et al.
Published: (2022-08-01) -
Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization
by: Rui Gao, et al.
Published: (2021-01-01) -
Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders
by: Gideon Obasanmi, PhD, et al.
Published: (2022-06-01)